MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10815-022-02548-3

Медицинская библиотека · Journal of assisted reproduction and genetics · 2022

Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents.

Maristany Sumiko, DuVall Adam S, Stock Wendy, Adeleye Amanda J

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

Recent advances in targeted therapy with monoclonal antibodies have significantly improved outcomes for people with cancer, sometimes allowing patients to avoid ovotoxic agents altogether. The current understanding is that monoclonal antibody cancer therapies that are not targeted to ovarian antigens should not impact ovarian reserve or increase the risk of primary ovarian insufficiency (POI). We present a case of rapid onset POI in a 23-year-old patient following chemotherapy for relapse/refractory B-cell acute lymphoblastic leukemia with a monoclonal antibody drug-conjugate, inotuzumab ozogamicin, that targets CD22. She was also treated with intrathecal methotrexate, cytarabine, and vincristine which are typically considered low risk for ovotoxicity. She was ovulatory with an AMH of 1.0 ng/mL prior to treatment and 2 months later was found to have an undetectable AMH. The patient experienced a canceled fertility preservation cycle due to an absent response to gonadotropins during ovarian stimulation. Consideration should be given to potential gonadal effects of monoclonal antibody therapies that may not have previously been explored.

Для цитирования: Maristany Sumiko, DuVall Adam S, Stock Wendy, Adeleye Amanda J. Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents.. Journal of assisted reproduction and genetics. 2022. DOI: 10.1007/s10815-022-02548-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.